JBC: Seeking an off switch for celiac disease
Celiac disease is an autoimmune disorder that affects, by some estimates, nearly one in 100 people. Celiac symptoms ar triggered by gluten, a protein found in wheat and related plants, but gluten doesn’t act alone to cause the digestive problems that patients suffer. Rather, gluten induces an overactive immune response when it’s modified by the enzyme transglutaminase 2, or TG2, in the small intestine.
Research published in the Journal of Biological Chemistry identifies an enzyme that turns off TG2, potentially paving the way for new treatments for celiac disease. Michael Yi, a chemical engineering graduate student at Stanford University, led the study.
“Currently, therapies to treat people with celiac disease are lacking,” Yi said. “The best approach right now is just a strict adherence to a lifelong gluten-free diet. Perhaps the reason behind this is our relatively poor understanding of TG2.”
The biochemistry of how TG2 interacts with gluten and induces an immune response has been well studied, but more basic mysteries remain, such as how TG2 behaves in people without celiac disease. Chaitan Khosla, the Stanford professor and director of Stanford Chemistry, Engineering & Medicine for Human Health, who oversaw the new study, has done research showing that TG2 can be active or inactive, depending on the forming or breaking of a specific chemical bond, called a disulfide bond, between two amino acids in the enzyme.
“Even though there’s a lot of transglutaminase 2 protein in the (small intestine), it’s all inactive,” Khosla said. “When it became clear that even though the protein was abundant, its activity was nonexistent in a healthy organ, the question became ‘What turns the protein on, and then what turns the protein off?’”
In 2011, Khosla’s team identified the enzyme that activates TG2 by breaking its disulfide bond. In the new paper, the researchers did experiments in cell cultures and found an enzyme that re-forms this bond, inactivating TG2. This enzyme, ERp57, is known mainly for helping fold proteins inside the cell. When it turns off TG2, it does so outside of cells, raising more questions about its functions in healthy people.
“Nobody really understands how (Erp57) gets outside the cell,” Khosla said. “The general thinking is that it’s exported from the cell in small quantities; this particular observation suggests that it actually does have a biological role outside the cell.”
TG2 is now the first protein known to have a reversible disulfide bond on/off switch of this type.
“This is a very different kind of on-and-off chemistry than the kind that medicinal chemists would (typically) use,” Khosla said.
Understanding this mechanism has led the team to investigate whether any drugs approved by the Food and Drug Administration could target the switch directly. Because previous studies have suggested that lack of TG2 doesn’t seem to affect the health of mice negatively, blocking TG2 is a promising avenue for treating celiac disease patients without requiring lifelong dietary changes.
Enjoy reading ASBMB Today?
Become a member to receive the print edition monthly and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

FDA approves CRISPR–Cas9 therapy for sickle cell disease
The gene editing treatment from Vertex Pharmaceuticals and CRISPR Therapeutics is the first of its kind

From the journals: MCP
Metals contaminate protein samples. Lipid droplets go haywire in Huntington’s. Nerve cells respond to stimulation. Read about these recent papers.

The perfect storm
The world has 2023 Nobel laureates Katalin Karikó, Drew Weissman and others to thank for laying a foundation for the COVID-19 vaccine decades before the pandemic.

Throw your hat in the ring!
Apply to speak at Discover BMB in Chicago in 2025.

How bacteria inhibit gene expression
Researchers show how altering activity of the transcription factor CarD can cause downregulation and upregulation of some genes.

Where the heck did all those structures inside complex cells come from?
Scientists agree that eons ago, a bacterium took up residence inside another cell and became its powerhouse, the mitochondrion. But there are competing theories about the birth of other organelles such as the nucleus and endoplasmic reticulum.